TORONTO

多伦多

,

，

May 26, 2026

2026年5月26日

/PRNewswire/ - iGan Partners, together with its funds (

/PRNewswire/ - iGan Partners及其基金（

https://iganpartners.com

https://iganpartners.com

), is pleased to announce its investment in

），很高兴宣布其投资于

Adenocyte™

腺细胞™

(

(

https://adenocyte.com

https://腺细胞.com

), a medical technology company pioneering the very early detection of pancreatic cancer and its precancerous precursors. Its LINFU® system has entered clinical use for the screening of high-risk patients. The 30-minute outpatient procedure is generally already reimbursed by both Medicare and many commercial insurance plans under existing CPT billing codes and utilizes technology that is FDA-cleared..

），这是一家医疗技术公司，致力于早期检测胰腺癌及其癌前病变。其LINFU®系统已进入临床应用，用于高危患者的筛查。这项30分钟的门诊手术通常已经由联邦医疗保险和许多商业保险计划根据现有的CPT计费代码进行报销，并且使用的是FDA认证的技术。

Continue Reading

继续阅读

Pioneering the early detection of pancreatic cancer with LINFU® technology. (CNW Group/iGan Partners)

利用LINFU®技术开创胰腺癌早期检测的先河。（CNW集团/iGan合作伙伴）

iGan and its funds led the first close of Adenocyte's $10M financing round, with the final close anticipated in June. The proceeds will support clinical and commercial expansion and continued technical development of the company's proprietary LINFU® platform for cytological sampling of the pancreas, breast, and prostate..

iGan及其基金领投了Adenocyte公司1000万美元融资轮的首轮融资，最终融资预计将于6月完成。所得款项将用于支持公司专有的LINFU®平台在胰腺、乳腺和前列腺细胞学取样方面的临床和商业扩展，以及持续的技术开发。

Adenocyte's patented LINFU® technology combines microbubble injection with proprietary low-intensity non-focused ultrasound to safely release epithelial cells for cytological analysis. The platform is designed to detect pancreatic precancer and very early cancer in high-risk populations, including patients with a pancreatic cyst, a family history of the disease, and a BRCA mutation..

腺细胞公司获得专利的LINFU®技术结合了微泡注射和专有的低强度非聚焦超声波，可以安全释放上皮细胞用于细胞学分析。该平台旨在检测高风险人群中的胰腺癌前病变和极早期癌症，包括胰腺囊肿患者、有家族病史的人群以及BRCA基因突变携带者。

Adenocyte has achieved a series of important milestones:

腺细胞已经取得了一系列重要里程碑：

Initial clinical deployment at several U.S. endoscopy

美国几家内窥镜检查机构的初步临床部署

centers with over 150 patient procedures successfully completed to date.

已完成超过150例患者手术的中心。

Presentation of results from the first 90 high-risk asymptomatic patients screened with LINFU

使用LINFU筛查的前90名高风险无症状患者的结果展示

®

®

at the U.S. and Canadian Academy of Pathology Annual Meeting (USCAP),

在美国和加拿大病理学会年会（USCAP）上，

demonstrating with 100% specimen adequacy and specificity the detection of 4 cases of unsuspected neoplasia, including a T1N0 adenocarcinoma, that were not detectable with any other modality including EUS, MRI, or FNA.

通过100%的样本充分性和特异性，检测出4例未被怀疑的肿瘤病例，包括一例T1N0腺癌，这些病例通过其他任何方法（包括EUS、MRI或FNA）都无法检测到。

A

A

collaboration

协作

with Quest Diagnostics

与Quest Diagnostics合作

to provide national laboratory services for the processing of LINFU® enhanced pancreatic cytology samples at Quest and AmeriPath laboratories in Tampa, Florida.

为佛罗里达州坦帕的Quest和AmeriPath实验室提供处理LINFU®增强型胰腺细胞学样本的国家实验室服务。

Quest Pap Smear for the Pancreas

胰腺的Quest Pap涂片检查

A growing pipeline of leading pancreatic centers that are preparing to adopt LINFU®

越来越多的领先的胰腺中心准备采用LINFU®

screening of high-risk patients in the coming quarters, positioning the company for meaningful commercial expansion in 2026.

在接下来的几个季度中对高风险患者进行筛查，为公司在2026年实现有意义的商业扩展做好准备。

'At iGan Partners, we invest in clinically important platforms that can deliver practical, measurable impact,' said Sam Ifergan, Founder and Managing Partner of iGan Partners. 'Pancreatic cancer is one of the deadliest cancers specifically because it is detected too late. Adenocyte's LINFU® platform offers a reimbursable, scalable way to find this disease earlier, when treatment can be curative, and it is already in use at leading U.S.

“在iGan Partners，我们投资于具有临床重要性且能带来实际、可衡量影响的平台，”iGan Partners创始人兼管理合伙人Sam Ifergan表示。“胰腺癌是最致命的癌症之一，特别是因为它通常发现得太晚。Adenocyte的LINFU®平台提供了一种可报销、可扩展的方式来更早地发现这种疾病，以便治疗可以达到治愈效果，并且该平台已经在美国一些领先的机构中投入使用。”

centers. We are proud to support Mark and the Adenocyte team as they bring LINFU® to many more patients.'.

中心。我们很自豪能够支持马克和阿德诺赛特团队，因为他们将LINFU®带给更多患者。'

'We are impressed by Sam Ifergan and the iGan team's understanding of and dedication to the advancement of disruptive, life-saving medical technology, and are excited about our partnership' said Dr. Mark Rutenberg, founder and CEO of Adenocyte.

“我们对萨姆·伊费尔甘和iGan团队在颠覆性、挽救生命的医疗技术方面的理解和奉献精神印象深刻，并对我们的合作感到兴奋，”阿德诺赛特公司的创始人兼首席执行官马克·鲁滕贝格博士说道。

About Adenocyte

关于腺细胞

Adenocyte (

腺细胞 (

www.adenocyte.com

www.adenocyte.com

) is a privately held medical technology company focused on the early detection of adenocarcinoma and its precancerous precursors.  Its patented LINFU® platform utilizes microbubble-enhanced low-intensity non-focused ultrasound to safely release pancreatic epithelial cells for cytological analysis, enabling detection of glandular dysplasia and very early carcinoma.

是一家私人持有的医疗技术公司，专注于腺癌及其癌前病变的早期检测。其获得专利的LINFU®平台利用微泡增强的低强度非聚焦超声波安全释放胰腺上皮细胞以进行细胞学分析，从而实现对腺体异型增生和极早期癌症的检测。

The procedure is reimbursed by Medicare and commercial insurance using existing CPT codes for the screening of patients at elevated risk for pancreatic cancer, and utilizes technology that is FDA, CE, and AMAR cleared for clinical use. The Adenocyte platform for the detection of ductal adenocarcinoma is supported by a growing portfolio of issued and pending patents, including its application to both breast and prostate cancer.

该程序通过现有的CPT代码对胰腺癌高风险患者进行筛查，并由Medicare和商业保险报销，同时使用了获得FDA、CE和AMAR临床使用许可的技术。Adenocyte平台用于检测导管腺癌，得到了越来越多的已颁发和正在申请的专利支持，包括其在乳腺癌和前列腺癌中的应用。

Based in Haifa and Jerusalem Israel, Adenocyte performed its preclinical testing at the Technion Preclinical Research Authority with investment from the Israel Innovation Authority and the Gedalia Doron Research Fund at the Israel Cancer Association..

总部位于以色列海法和耶路撒冷的Adenocyte公司在Technion临床前研究机构进行了临床前测试，并获得了以色列创新局和以色列癌症协会Gedalia Doron研究基金的投资。

About iGan Partners

关于iGan Partners

iGan Partners is a North American venture capital firm focused on driving meaningful change in healthcare through investments in early and growth-stage companies. We partner with visionary entrepreneurs who are building enterprise technologies to improve patient outcomes, increase operational efficiency, and deliver systemic transformation..

iGan Partners是一家北美风险投资公司，专注于通过投资早期和成长期公司来推动医疗保健领域的有意义变革。我们与富有远见的企业家合作，他们正在构建企业技术以改善患者治疗效果、提高运营效率并实现系统性转型。

SOURCE iGan Partners

来源：iGan Partners

21

21

%

%

more press release views with

更多新闻发布视图与

Request a Demo

请求演示